摘要
匹杉醇为一新型蒽环类药物,已由欧盟批准单独用于治疗成人复发难治侵袭性B细胞非霍奇金淋巴瘤。Ⅲ期临床试验结果提示,作为复发难治侵袭性非霍奇金淋巴瘤的单一替换疗法,匹杉醇的疗效明显优于单独应用长春瑞滨、奥沙利铂、异环磷酰胺、依托泊苷、米托蒽醌、吉西他滨等对照药物。患者对匹杉醇易于耐受,与其他蒽环类药物相比,匹杉醇的心脏毒性较低,骨髓抑制为其最常引起的不良事件。
Pixantrone is a novel anthraeenedione. It has been approved in the EU as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non- Hodgkin＇s B- cell lymphoma. In the phase III trial, the efficacy of pixantrone was significantly higher than vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone or gemcitabine. Pixantrone is generally well tolerated and with a manageable adverse event profile. Pixantrone has much less toxic toward myocytes than other anthracenediones. Myelosuppression is the most commonly occurring adverse event.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2018年第1期17-20,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
匹杉醇
抗肿瘤药
淋巴瘤
非霍奇金
葸环类药物
pixantrone
antineoplastic agents
lymphoma, non- Hodgkin＇ s
anthracenediones
